Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus PROVERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus PROVERA.
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs PROVERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone acetate (progestin) and ethinyl estradiol (estrogen) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial lining to reduce implantation. Ethinyl estradiol (in 7-day extended regimen) maintains hormone levels. Ferrous fumarate provides iron supplementation.
Provera (medroxyprogesterone acetate) is a progestin that binds to progesterone receptors, suppressing gonadotropin secretion, inhibiting endometrial growth, and inducing secretory changes in the endometrium. It also has antigonadotropic effects by reducing LH and FSH release from the pituitary.
One tablet (containing norethindrone acetate 1 mg, ethinyl estradiol 20 mcg, and ferrous fumarate 75 mg) orally once daily for 28-day cycle (21 active pills, 7 placebo with ferrous fumarate).
Oral: 5-10 mg daily for 5-10 days for secondary amenorrhea; 5-10 mg daily for 12-14 days per cycle in combination with estrogen for endometrial hyperplasia; 400-1000 mg/day IM monthly for endometriosis.
None Documented
None Documented
Norethindrone: Terminal half-life approximately 8–11 hours. Ethinyl estradiol: Terminal half-life approximately 13–27 hours (mean 17 hours). Clinical context: Steady state reached after 5–7 days.
Terminal elimination half-life is approximately 12-17 hours for medroxyprogesterone acetate (oral). With depot intramuscular injection, the half-life is extended to approximately 50 days due to slow absorption from the injection site.
Norethindrone acetate: Urine (39% as metabolites, 1% unchanged); Feces (35% as metabolites). Ethinyl estradiol: Urine (40% as glucuronide conjugates, <1% unchanged); Feces (40% as metabolites). Ferrous fumarate: Iron absorbed and utilized; unabsorbed iron excreted in feces.
Renal (50-60% as metabolites), biliary/fecal (30-40%). Less than 1% excreted unchanged.
Category D/X
Category C
Progestin
Progestin